Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The anti-leukemic activity of sodium dichloroacetate in p53mutated/null cells is mediated by a p53-independent ILF3/p21 pathway.

Oncotarget - 10 Feb 2015

Agnoletto Chiara, Brunelli Laura, Melloni Elisabetta, Pastorelli Roberta, Casciano Fabio, Rimondi Erika, Rigolin Gian Matteo, Cuneo Antonio, Secchiero Paola, Zauli Giorgio

Abstract excerpt

B-chronic lymphocytic leukemia (B-CLL) patients harboring p53 mutations are invariably refractory to therapies based on purine analogues and have limited treatment options and poor survival. Having recently demonstrated that the mitochondria-targeting small molecule sodium dichloroacetate (DCA) exhibits anti-leukemic activity in p53wild-type B-CLL cells, the aim of this study was to evaluate the effect of DCA in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blotting, Western
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p21

Share to Gene Expression Regulation, Leukemic

Share to HL-60 Cells

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to RNA Interference

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 25544776
DOI: 10.18632/oncotarget.2960
PMCID: PMC4385858

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The anti-leukemic activity of sodium dichloroacetate in p53mutated/null cells is mediated by a p53-independent ILF3/p21 pathway.PMID 25544776Read ↗

The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer DrugsSemantic proximity Read ↗

Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROS-mediated mechanism.Semantic proximity Read ↗

PRIMA-1MET cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells.Semantic proximity Read ↗

5-Aza-2′-deoxycytidine Activates the p53/p21Waf1/Cip1 Pathway to Inhibit Cell ProliferationSemantic proximity Read ↗

Nicotinamide Blocks Proliferation and Induces Apoptosis of Chronic Lymphocytic Leukemia Cells through Activation of the p53/miR-34a/SIRT1 Tumor Suppressor NetworkSemantic proximity Read ↗

p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells.Semantic proximity Read ↗

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).Semantic proximity Read ↗

Dichloroacetate inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cellsSemantic proximity Read ↗

Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.Semantic proximity Read ↗

Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIMSemantic proximity Read ↗

5‐Aza‐2′‐deoxycytidine induces p21<sup>WAF</sup> expression by demethylation of p73 leading to p53‐independent apoptosis in myeloid leukemiaSemantic proximity Read ↗

Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.